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Abstract
Introduction:	New	methods	for	coagulation	tests	require	careful	assessment	before	
routine	use.	We	evaluated	the	analytical	performance	of	five	new	coagulation	assays	
for	 measuring	 prothrombin	 time	 (PT)	 and	 activated	 partial	 thromboplastin	 time	
(aPTT).
Methods:	 PT	 Rec,	 PT	Owren,	 aPTT,	 aPTT	 Lupus	 and	 aPTT	 Screen	 assays	 (Roche	
Diagnostics)	 were	 evaluated	 on	 cobas t 711 and cobas t	 511	 analysers	 (Roche	
Diagnostics)	at	four	European	centres.	Analytical	performance	and	method	compari-
sons	 with	 relevant	 commercially	 available	 assays	 were	 performed	 to	 Clinical	
Laboratory	Standards	Institute	guidelines	using	residual	anonymized	samples.	Lot-	to-	
lot	comparison	and	equivalency	of	the	cobas t analysers were also assessed; refer-
ence	ranges	were	determined	using	samples	from	apparently	healthy	volunteers.
Results:	Overall,	coefficients	of	variation	were	≤1.3%	for	within-	run	precision	and	
≤6.3%	for	total	reproducibility	across	all	sites.	Deming	regression	analyses	showed	
good	 agreement	 between	 each	 assay	 (cobas t	 711)	 and	 respective	 comparator	
method	 (Pearson’s	 r:	 0.964-	0.999,	n	>	120	 samples/assay/site).	Passing–Bablok	 re-
gression	analyses	demonstrated	equivalence	of	 the	 two	cobas t	platforms	 for	use	
with	each	assay	(Pearson’s	r	≥	0.995).	Lot-	to-	lot	consistency	was	high	for	all	assays	
and	comparisons	 (Pearson’s	 r	≥	0.998).	Reference	 ranges	 (2.5th-	97.5th	percentiles;	
n	=	200	 samples/assay)	 in	 seconds	were	 8.4-	10.6	 (PT	 Rec),	 18.2-	27.2	 (PT	Owren),	
23.6-	30.6	(aPTT),	24.1-	31.7	(aPTT	Lupus)	and	23.9-	33.2	(aPTT	Screen).
Conclusion:	Based	on	the	excellent	analytical	performance	and	good	agreement	with	
relevant	comparator	methods,	the	five	coagulation	assays	on	the	novel	cobas t 711 
and cobas t	511	analysers	are	suitable	for	routine	use	in	core	laboratories.
K E Y W O R D S
activated	partial	thromboplastin	time,	coagulation	analyser,	prothrombin	time
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution-NonCommercial	License,	which	permits	use,	distribution	and	reproduction	
in	any	medium,	provided	the	original	work	is	properly	cited	and	is	not	used	for	commercial	purposes.
©	2018	The	Authors.	International Journal of Laboratory Hematology	Published	by	John	Wiley	&	Sons	Ltd
2  |     KITCHEN ET al.
1  | INTRODUC TION
Coagulopathies	occur	in	patients	across	all	healthcare	settings,	often	
resulting	in	clinically	significant	bleeding	or	thrombosis,	depending	
on	the	nature	of	the	defect.1-6	A	number	of	possible	aetiologies	exist,	
including	trauma,	disease	(eg,	liver	disease,	sepsis,	cancer),	surgery,	
pharmacological	treatment	(eg,	unfractionated	heparin	[UFH],	vita-
min	K	antagonists,	direct	factor	Xa-	and	direct	thrombin	inhibitors)	
and	genetic	or	acquired	deficiencies	in	coagulation	factors.3,7-11	The	
ability	to	accurately,	reliably	and	quickly	measure	indicators	of	hae-
mostatic	function,	and	to	subsequently	implement	corrective	mea-
sures,	is	thus	important	for	patient	health.
Coagulation	 tests	 are	 used	widely	 for	 the	 screening,	 diagnosis	
and	assessment	of	coagulopathies,	and	for	the	monitoring	of	antico-
agulant	and	antithrombotic	therapies.5,8-10,12-19	In	particular,	assess-
ments	of	prothrombin	time	(PT)	and	activated	partial	thromboplastin	
time	(aPTT),	relating	to	the	activity	of	the	extrinsic/common	and	in-
trinsic/common	 pathways	 of	 coagulation,	 respectively,	 are	 widely	
used	to	detect	hypocoagulation.4,5,8,15-17,20-25
The	current	generation	of	automated,	high-	throughput	coagula-
tion	analysers	provides	scope	for	improved	turnaround	times	in	core	
laboratories,	as	well	as	for	potential	expansion	of	the	range	of	tests	
offered.	Five	new	commercially	available	assays	(PT	Rec,	PT	Owren,	
aPTT,	aPTT	Lupus	and	aPTT	Screen)	have	recently	become	available	
for use on cobas t	coagulation	analysers,	and	may	offer	potential	ad-
vantages	over	existing	assays/platforms	in	terms	of	handling,	preci-
sion	and	throughput.	Prior	to	their	adoption,	it	is	important	that	new	
assays	are	evaluated	for	precision,	compared	with	existing	methods	
and	 that	 relevant	 reference	 ranges	 are	 established,	 thus	 ensuring	
that	the	assays	are	suitable	for	routine	use	in	core	laboratories	and	
able	to	reliably	inform	clinical	decisions.26,27
This	 multicentre	 study	 evaluated	 the	 performance	 of	 the	 five	
new	 coagulation	 assays	 on	 the	 cobas t	 analysers.	 For	 each	 assay,	
the	 analytical	 performance	was	evaluated	 and	a	method	 compari-
son	with	existing,	commercially	available	assays/platforms	was	per-
formed;	reference	ranges	for	each	assay	were	also	determined	using	
samples	from	apparently	healthy	volunteers.
2  | MATERIAL S AND METHODS
2.1 | Study design
The	study	was	performed	between	June	2016	and	March	2017	 in	
core	laboratories	at	four	centres	 in	Europe	(University	of	Freiburg,	
Germany;	Royal	Hallamshire	Hospital,	 Sheffield,	UK;	University	of	
Debrecen,	Hungary;	AKH	Wien,	Austria).
Five	 assays	 (PT	 Rec,	 PT	 Owren,	 aPTT,	 aPTT	 Lupus	 and	 aPTT	
Screen;	Roche	Diagnostics	GmbH,	Mannheim,	Germany)	were	each	
evaluated	 for	 their	 analytical	 performance,	 and	 compared	 with	
existing	 methodologies/technologies	 (see	 below)	 in	 independent	
method	 comparison	 experiments;	 lot-	to-	lot	 variability,	 the	 equiva-
lency	of	each	assay	on	two	cobas t	platforms	and	reference	ranges	
in	apparently	healthy	volunteers	were	also	assessed.	All	assays	and	
instruments	were	used	according	to	their	respective	manufacturers’	
instructions	and	quality	control	measurements	were	performed	at	
least	twice	every	day,	to	monitor	the	appropriate	function	of	each	
analyser.	 Anonymized	 human	 residual	 (3.2%	 [0.109M])	 sodium	
citrate	 plasma	 samples	 were	 used	 for	 all	 experiments;	 samples	
for	 reference	 range	 evaluation	 were	 sourced	 from	 a	 blood	 bank	
(Freiburg,	 Germany).	 Samples	 were	 double-	spun	 (10	minutes	 at	
3300	g	followed	by	10	minutes	at	2700	g)	before	freezing	at	−80°C	
and	shipment	on	dry	ice.	Samples	were	subsequently	stored	below	
−60°C,	and	storage	conditions	were	similar	between	different	sam-
ple	 sources.	 Sample	 tubes	 were	 sourced	 from	 Becton-	Dickinson	
and	 Company	 (Wokingham,	 UK),	 Sarstedt	 AG	 &	 Co.	 (Nümbrecht,	
Germany),	or	Greiner	Bio	One	International	GmbH	(Kremsmünster,	
Austria).
Independent	ethics	committee	approval	or	waiver	was	obtained	
where	 necessary	 before	 study	 initiation	 according	 to	 local	 laws	
and	 guidelines.	 The	 study	was	performed	 according	 to	 the	princi-
ples	of	the	Declaration	of	Helsinki	and	International	Conference	on	
Harmonisation	Good	Clinical	Practice	guidelines.
2.2 | Assay principles
The	 PT	 Rec	 assay	 contains	 thromboplastin	 (recombinant	 human	
thromboplastin	 reagent	 containing	 a	 heparin-	neutralizing	 sub-
stance)	and	calcium,	which	initiate	the	activation	of	the	extrinsic	
coagulation	cascade	when	added	to	citrated	human	plasma.23	The	
PT	Owren	assay	reagent	contains	rabbit	brain	thromboplastin	plus	
bovine	plasma	(containing	factor	V	and	fibrinogen	and	lacking	fac-
tors	II,	VII	and	X)	and	a	heparin	neutralizer.28	For	both	assays,	the	
time	between	the	addition	of	 the	 reagent	 to	 the	plasma	and	the	
formation	of	the	fibrin	clot	was	measured	and	reported	in	seconds,	
international	normalized	ratio	(INR),	or	percentage	of	normal.	Due	
to	the	inclusion	of	a	heparin	neutralizer,	presence	of	UFH	does	not	
affect	the	PT	clotting	time	of	either	assay.	The	assays	are	intended	
as	 an	 aid	 for	management	 of	 vitamin	 K	 antagonist	 therapy,	 and	
the	PT	Rec	and	aPTT	assays	can	also	assist	diagnosis	of	fibrinogen	
deficiency.
The	aPTT	assay	reagent	consists	of	ellagic	acid	as	surface	acti-
vator	and	purified	soy	phosphatides	with	added	buffer,	stabilizer	
and	preservative.	The	aPTT	Lupus	assay	reagent	consists	of	ellagic	
acid	 as	 surface	 activator	 and	 a	 blend	 of	 purified	 soy	 and	 rabbit	
brain	phosphatides	with	added	buffer,	stabilizer	and	preservative.	
The	aPTT	Screen	assay	reagent	consists	of	silicon	dioxide	particles	
as	activator	and	a	blend	of	purified	soy	phosphatides	with	added	
buffer,	stabilizers	and	preservative.	For	each	aPTT	assay,	the	ad-
dition	 of	 calcium	 chloride	 prompts	 the	 initiation	 of	 the	 intrinsic	
coagulation	cascade	and	the	time	from	the	addition	of	the	calcium	
chloride	until	clot	formation	is	measured.18,20,25,29	The	aPTT	assay	
is	designed	to	have	reduced	sensitivity	to	lupus	anticoagulant	(LA),	
while	 the	aPTT	Lupus	assay	has	 increased	sensitivity	 to	LA.	The	
aPTT	Screen	assay	is	designed	to	have	the	highest	sensitivity	to-
wards	UFH.
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2.3 | Analytical performance
Following	a	familiarization	phase,	within-	run	precision	of	each	assay	
was	 evaluated;	 reproducibility	 was	 also	 evaluated	 according	 to	
Clinical	Laboratory	Standards	Institute	(CLSI)	EP05-	A3	guidelines.30 
Each	assay	was	independently	evaluated	on	the	cobas t 711 analyser 
(high-	throughput:	390	tests/h;	evaluated	at	all	four	sites)	and	cobas 
t	511	analyser	(mid-	throughput:	195	tests/h;	evaluated	at	two	sites	
[UK;	Germany]).	Within-	run	precision	for	each	assay	was	evaluated	
in	one	 run	using	 two	 (PT	Rec,	PT	Owren)	or	 three	controls	 (aPTT,	
aPTT	Lupus,	aPTT	Screen)	and	five	human	plasma	samples	 (n	=	21	
replicates	per	sample),	covering	the	measuring	range;	each	site	per-
formed	their	experiments	with	an	individual	reagent	and	control	lot,	
which	varied	by	site.
Reproducibility	 was	 evaluated	 over	 5	days	 using	 two	 or	 three	
controls	and	five	human	plasma	pools	(one	aliquot	of	each	measured	
five	times	daily),	covering	the	measuring	range;	 three	different	 re-
agent	lots	(one	per	site)	and	the	same	control	lots	were	used	across	
all	sites.	Results	were	evaluated	across	the	study	sites.
2.4 | Method comparison
Method	 comparison	 was	 performed	 for	 each	 assay	 (cobas t 711 
analyser)	 vs	 the	 following	 comparator	methods,	 according	 to	CLSI	
EP09-	A3	 guidelines31:	 (a)	 PT	 Rec	 vs	 Innovin	 (Siemens	Healthcare,	
Marburg,	 Germany)	 on	 Sysmex	 CS-	5100	 or	 CS-	2000i	 (Sysmex,	
Kobe,	Japan);	(b)	PT	Owren	vs	Hepato-	Prest	(Diagnostica	Stago	SAS,	
Asnières-	sur-	Seine,	France)	on	Stago	STA-	R	Evolution	 (Diagnostica	
Stago	SAS);	 (c)	 aPTT	vs	Actin	FS	 (Siemens	Healthcare)	 on	Sysmex	
CS-	5100	or	CS-	2000i,	and	aPTT	vs	STA	Cephascreen	(Diagnostica	
Stago	SAS)	on	Stago	STA-	R	Evolution	(performed	in	Mannheim	only);	
(d)	 aPTT	Lupus	vs	Actin	FSL	 (Siemens	Healthcare)	on	Sysmex	CS-	
5100	 or	 CS-	2000i,	 and	 aPTT	 Lupus	 vs	 STA	 Cephascreen/STA-	LA	
(Diagnostica	 Stago	 SAS)	 on	 Stago	 STA-	R	 Evolution	 (performed	 in	
Mannheim	 only);	 and	 (e)	 aPTT	 Screen	 vs	 Pathromtin	 SL	 (Siemens	
Healthcare)	on	Sysmex	CS-	5100	or	CS-	2000i.	Except	for	the	aPTT	
method	comparison	vs	comparator	assays	on	Stago	STA-	R	Evolution,	
each	comparison	was	performed	at	three	or	four	sites	(one	reagent	
lot	 per	 site),	 using	 a	minimum	of	 120	 residual	 anonymized	 human	
plasma	 samples	 per	 assay,	 per	 site	 (representing	 the	 appropriate	
measuring	range).	The	measuring	ranges	tested	for	each	assay	were	
as	follows:	PT	Rec,	up	to	INR	5.5	or	approximately	60	seconds;	PT	
Owren,	 up	 to	 INR	 5.5	 or	 approximately	 150	seconds;	 aPTT,	 aPTT	
Screen	and	aPTT	Lupus,	up	to	175	seconds	for	each	assay.
2.5 | Equivalency of the cobas t analysers
Equivalency	of	the	cobas t 511 and cobas t	711	platforms	was	evalu-
ated	by	method	comparison,	using	each	of	the	five	assays	(PT	Rec,	
PT	Owren,	aPTT,	aPTT	Lupus	and	aPTT	Screen).	A	minimum	of	120	
anonymized	human	plasma	samples	were	 tested	on	each	platform	
at	each	of	the	two	sites	(Freiburg	and	Sheffield;	one	reagent	lot	per	
site).
2.6 | Lot- to- lot comparison
Lot-	to-	lot	comparability	was	assessed	for	each	assay	on	the	cobas 
t	711	analyser.	Each	assay	was	tested	using	three	reagent	lots	(two	
lots	per	site)	and	a	minimum	of	120	anonymized	human	plasma	sam-
ples	per	comparison.
2.7 | Reference range studies
Reference	ranges	for	each	assay	were	determined	using	anonymized	
residual	samples	from	apparently	healthy	adult	donors	(0.109M/3.2%	
citrate)	sourced	from	a	blood	bank;	samples	were	measured	fresh	at	
the	sampling	site	in	Freiburg,	Germany.	Inclusion	criteria	were	appar-
ently	healthy	adults	(aged	18-	50	years	and	originating	from	Europe	
or	the	US)	and	able	to	provide	written	informed	consent;	exclusion	
criteria	were	self-	declared	pregnancy	or	breast-	feeding,	and	use	of	
anticoagulation	medication	 including	but	not	 limited	to	acetyl	sali-
cylic	 acid,	 direct	 oral	 anticoagulants,	 phenprocoumon	 and	 warfa-
rin.	Experiments	were	performed	with	three	different	reagent	 lots	
(N	=	200;	n	≈67	samples	per	 lot).	Reference	 ranges	 for	each	assay	
were	 also	 determined	 using	 frozen	 0.109M/3.2%	 citrated	 sam-
ples	 (BIOMEX	GmbH,	Heidelberg,	Germany;	 plasma	 frozen	within	
1	hour	of	sampling)	purchased	in	Becton-	Dickinson	tubes	(San	Jose,	
CA,	USA)	and	in	aliquots	of	the	anonymized	residual	samples	from	
healthy	adult	donors,	collected	in	Sarstedt	tubes.	The	time	between	
sampling	and	measurement	 for	 reference	 range	samples	was	 typi-
cally	 1-	3	hours	 (Sarstedt	 tubes).	 To	 obtain	 frozen	 ranges	 (Sarstedt	
tubes),	these	samples	were	immediately	frozen	after	measurement	
of	 the	 Sarstedt	 fresh	 ranges.	 Both	 frozen	 sample	 types	 (Sarstedt	
and	Becton-	Dickinson)	were	measured	at	three	different	sites	after	
thawing	(one	reagent	lot	per	site).
2.8 | Sensitivity analysis of aPTT, aPTT 
Lupus and aPTT Screen assays to heparin and lupus 
anticoagulant
Sensitivity	 of	 the	 three	 new	 aPTT	 assays	 towards	 UFH	 and	 LA	
was	analysed.	The	presence	of	warfarin	 (UFH	analyses)	or	any	an-
ticoagulant	 (LA	analyses)	therapy	was	excluded	by	testing	with	PT	
(Thromborel	 S	 reagent),	 TT	 (BC	 Thrombin)	 and	 anti-	Xa	 (Hyphen	
Biophen	UFH	Liquid	Reagent	Technology).	 Therapeutic	 ranges	 for	
the	three	aPTT	assays	were	also	determined	according	to	CLSI	H47-	
A2	guidelines,	using	linear	regression.
Platelet-	poor	samples	 (n	=	117)	were	sourced	from	patients	re-
ceiving	UFH,	and	each	sample	was	measured	with	three	Roche	aPTT	
reagents	on	a	cobas t	711	analyser.	Results	were	compared	against	
measurements	from	three	Siemens	aPTT	reagents	 (Actin	FS,	Actin	
FSL	and	Pathrombin	SL)	on	a	BCS	XP	system.
Lupus	 anticoagulant-	positive	 plasma	 samples	 (n	=	96)	 were	
sourced	commercially	(Clinisys)	and	the	LA	ratio	determined	for	each	
sample	on	a	BCS	XP	system	with	LA1	and	LA2	reagents	(Siemens).	
The	sensitivity	of	the	three	aPTT	assays	on	a	cobas t 711 analyser 
was	assessed	by	comparison	with	the	LA	ratio.
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2.9 | Data analysis
Assay	output	was	captured	directly	using	WinCAEv,	a	CFR	21	Part	
11	compliant	electronic	data	capture	software	developed	and	vali-
dated	 for	 Roche-	sponsored	 studies.32	 The	 coefficient	 of	 variation	
(CV)	was	calculated	for	within-	run	precision	and	reproducibility	and	
compared	against	prespecified	acceptance	ranges	(within-	run	preci-
sion:	≤3.0%	[PT	Rec,	PT	Owren]	or	≤4.0%	[aPTT,	aPTT	Lupus,	aPTT,	
Screen];	 total	 reproducibility	 [all	assays]	≤25.0%),	which	were	con-
sistent	with	published	guidelines.33
For	method	comparisons	(comparator	method,	cobas t	platform	
and	 lot-	to-	lot),	 slope	 and	 intercept	 were	 calculated	 according	 to	
Passing–Bablok	or	Deming,	 and	Pearson’s	 r	 correlation	 coefficient	
was	estimated;	analyses	were	based	on	INR	for	the	PT	Rec	and	PT	
Owren	assays,	and	on	seconds	for	the	aPTT,	aPTT	Lupus	and	aPTT	
Screen	 assays,	 as	 acceptance	 criteria	were	 defined	 in	 these	 units.	
Bias	was	examined	using	Bland-	Altman	analysis.
Reference	ranges	(seconds)	were	calculated	based	on	the	2.5th	and	
97.5th	percentile	values	of	the	series	of	measurements	for	each	assay	
with	90%	confidence	intervals	(CI);	median	values	were	also	estimated.
3  | RESULTS
3.1 | Analytical performance
For	each	assay,	the	CVs	for	within-	run	precision	and	total	reproduc-
ibility	are	presented	in	Table	1;	all	values	were	within	the	prespeci-
fied	 acceptance	 criteria.	Across	 all	 five	 assays,	CVs	 for	within-	run	
precision	of	 the	human	 sample	pools,	 across	 all	 four	 sites,	 ranged	
from	0.2%	to	1.3%	on	the	cobas t	711	analyser,	and	from	0.1%	to	
0.8%	on	the	cobas t	511	analyser;	CVs	for	total	reproducibility	across	
all	four	sites	ranged	from	0.8%	to	3.4%	on	the	cobas t	711	analyser,	
and	from	0.3%	to	6.3%	on	the	cobas t 511 analyser.
3.2 | Method comparison
Method	 comparison	 experiments	 demonstrated	 good	 agree-
ment	for	each	assay	(cobas t	711)	vs	their	respective	comparator	
method	 according	 to	 prespecified	 criteria	 (specified	 in	 Product	
Specifications	 Document)	 based	 on	Deming	 regression	 analyses	
(Table	2).	For	each	comparison,	Pearson’s	correlation	coefficients	
(presented	 as	 a	 range	 across	 sites)	 confirmed	 an	 excellent	 cor-
relation	 between	 methods:	 PT	 Rec	 vs	 Innovin,	 r	=	0.988-	0.999;	
PT	 Owren	 vs	 Hepato-	Prest,	 r	=	0.990-	0.994;	 aPTT	 vs	 Actin	 FS,	
r	=	0.980-	0.986;	aPTT	vs	STA	Cephascreen,	r	=	0.819;	aPTT	Lupus	
vs	 Actin	 FSL,	 r	=	0.967-	0.987;	 aPTT	 Lupus	 vs	 STA	 Cephascreen,	
r	=	0.943;	 aPTT	 Lupus	 vs	 STA-	LA,	 r	=	0.958;	 aPTT	 Screen	 vs	
Pathromtin	 SL,	 r	=	0.964-	0.985;	 aPTT	 Screen	 vs	 aPTT	 on	 Stago	
STA-	R	Evolution,	r	=	0.833.	Bias	within	the	data	was	analysed	and	
is	shown	in	the	Bland-	Altman	analyses	for	cobas t 711	vs	compara-
tor	methods	(Figures	S1-S5).
3.3 | Equivalency of cobas t 711 and cobas t 
511 analysers
For	each	of	the	five	assays	evaluated,	the	cobas t 711 and cobas t 
511	platforms	demonstrated	equivalence,	according	to	prespecified	
acceptance	 criteria,	 based	 on	 Passing–Bablok	 regression	 analyses	
(Table	3).	Across	all	assays	(n	=	5)	and	sites	(n	=	2	sites	per	assay,	ex-
cept	PT	Owren	where	n	=	1	site),	Pearson’s	correlation	coefficient	
was	≥0.995.	Bland-	Altman	plots	are	presented	(Figures	S6-S10)	and	
demonstrate	 constant	bias	 for	 the	 five	 assays,	with	 consistent	 re-
sults	for	the	two	sites.
3.4 | Lot- to- lot comparison
A	high	level	of	consistency	between	lots	was	observed	for	all	five	as-
says	(cobas t	711	analyser);	the	specified	equivalence	criteria	based	
on	Passing–Bablok	analyses	were	met	(Table	4).	For	all	assays	(n	=	5)	
and	comparisons	 (Lot	2	vs	1,	Lot	3	vs	2	and	Lot	1	vs	3),	Pearson’s	
correlation	coefficient	was	≥0.998.	Bias	analysed	by	Bland-	Altman	
plots	are	presented	(Figures	S10-S15),	showing	constant	bias	for	the	
different	lots	and	consistent	results	between	sites.
3.5 | Reference range
Based	on	fresh	samples	 in	Sarstedt	tubes,	 reference	ranges	 (2.5th	to	
97.5th	percentiles	[90%	CI];	n	=	200	fresh	samples	per	assay)	in	seconds	
TABLE  1 Within-	run	precision	and	total	reproducibility	(across	all	four	sites)	of	the	five	coagulation	assays	on	the	cobas t 711 and cobas t 
511	analysers,	based	on	human	plasma	pools	(range	for	the	five	human	plasma	pools	is	presented)
Assay (s)
Within- run precision 
acceptance criteriaa(%)
Within- run precision, range of 
% CV
Total reproducibility 
acceptance criteriaa(%)
Total reproducibility, range 
of % CV
cobas t 711 cobas t 511 cobas t 711 cobas t 511
PT	Rec CV	≤	3.0 0.2-	0.7 0.1-	0.4 CV	≤	25.0 1.9-	3.2 2.2-	3.7
PT	Owren CV	≤	3.0 0.3-	0.8 0.2-	0.6 CV	≤	25.0 1.5-	3.4 0.7-	2.2
aPTT CV	≤	4.0 0.2-	1.1 0.1-	0.8 CV	≤	25.0 0.9-	2.9 0.8-	3.8
aPTT	Lupus CV	≤	4.0 0.2-	1.3 0.3-	0.7 CV	≤	25.0 0.8-	3.1 0.3-	2.2
aPTT	Screen CV	≤	4.0 0.3-	1.2 0.2-	0.8 CV	≤	25.0 1.4-	3.4 0.8-	6.3
aPTT,	activated	partial	thromboplastin	time;	CV,	coefficient	of	variation;	PT,	prothrombin	time.
aUnit	for	acceptance	criteria	is	PT	in	seconds.
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were	8.40	 (8.26-	8.48)	 to	10.6	 (10.3-	11.8;	PT	Rec),	18.2	 (17.2-	18.7)	 to	
27.2	(26.7-	29.5;	PT	Owren),	23.6	(23.3-	24.0)	to	30.6	(30.2-	31.0;	aPTT),	
24.1	(21.6-	24.7)	to	31.7	(31.1-	32.4;	aPTT	Lupus)	and	23.9	(20.5-	24.3)	to	
33.2	(32.9-	33.7;	aPTT	Screen;	Figure	1A).	Comparable	reference	ranges	
(90%	CI)	were	obtained	using	frozen	samples	stored	in	Sarstedt	tubes	
(n	=	200	samples	per	assay):	PT	Rec,	8.47	(8.35-	8.52)	to	10.6	(10.4-	11.9);	
PT	Owren,	18.2	(17.1-	18.8)	to	27.1	(26.7-	30.1);	aPTT,	23.6	(23.1-	24.1)	to	
30.8	(30.4-	31.5);	aPTT	Lupus,	24.6	(21.8-	24.9)	to	32.4	(31.5-	32.8);	aPTT	
Screen,	24.0	 (20.3-	24.6)	 to	34.3	 (33.6-	35.9).	 Similar	 reference	 ranges	
(90%	CI)	were	 also	obtained	using	 frozen	 samples	 stored	 in	Becton-	
Dickinson	tubes	(n	≥	150	samples	per	assay):	PT	Rec,	8.11	(7.84-	8.21)	to	
12.3	(11.4-	12.6);	PT	Owren,	18.8	(18.1-	18.9)	to	28.5	(27.1-	36.3);	aPTT,	
24.3	 (23.1-	24.5)	 to	 32.1	 (31.0-	34.6);	 aPTT	 Lupus,	 24.3	 (19.5-	24.7)	 to	
33.4	(32.4-	40.5);	aPTT	screen,	23.5	(21.7-	24.6)	to	39.8	(36.5-	57.7).
TABLE  2 Method	comparison:	cobas t	711	vs	comparator	device
Comparison Evaluation Acceptance criteriad
Freiburg Sheffield Debrecen Vienna Vienna
Lot 1 Lot 2 Lot 3 Lot 2 Lot 3
PT	Rec	vs	Innovina n 131 135 130
Slope	(Deming) 1.00 ± 0.10 1.008 1.036 0.900
Intercept NA 0.090 0.045 0.238
Pearson’s	r ≥0.900 0.999 0.997 0.988
Bias	at	1.0	INR 1	≤	0.15 0.097 0.081 0.138
PT	Owren	vs	Hepato-	Presta n 144 129 139
Slope	(Deming) 1.00 ± 0.10 0.853 0.845 0.833
Intercept NA 0.132 0.149 0.196
Pearson’s	r ≥0.900 0.994 0.993 0.990
Bias	at	1.0	INR 1	≤	0.15 −0.015 −0.006 0.029
aPTT	vs	Actin	FSb n 136 123 142 193
Slope	(Deming) 0.65-	1.35 1.037 1.061 1.040 0.953
Intercept NA 2.27 4.38 1.99 4.72
Pearson’s	r ≥0.850 0.986 0.982 0.980 0.980
aPTT	Lupus	vs	Actin	FSLb n 144 122 150 204
Slope	(Deming) 0.65-	1.35 1.041 1.286 1.126 1.098
Intercept NA 1.37 −5.86 −2.47 1.29
Pearson’s	r ≥0.850 0.967 0.983 0.987 0.982
aPTT	Screen	vs	Pathromtin	SLb n 132 125 139 183
Slope	(Deming) 0.65-	1.35 0.849 0.982 1.002 0.909
Intercept NA 4.27 −2.47 −2.37 3.32
Pearson’s	r ≥0.850 0.980 0.985 0.985 0.964
aPTT	vs	STA	Cephascreenb,c n 175
Pearson’s	r NAe 0.819
aPTT	Lupus	vs	STA	Cephascreenb,c n 99
Pearson’s	r NAe 0.943
aPTT	Lupus	vs	STA-	LAb,c n 128
Slope	(Deming) NAe 0.591
Intercept NAe 10.21
Pearson’s	r NAe 0.958
aPTT	Screen	vs	aPTTb,c n 153
Pearson’s	r NAe 0.833
aPTT,	activated	partial	thromboplastin	time;	INR,	international	normalized	ratio;	LA,	lupus	anticoagulant;	NA,	not	applicable;	PT,	prothrombin	time.
aAnalyses	based	on	INR.
bAnalyses	based	on	seconds.
cPerformed	at	one	site	only	(Mannheim,	Germany).
dUnits	for	acceptance	criteria	are	INR	for	PT	Rec	and	PT	Owren,	and	seconds	for	aPTT,	aPTT	Lupus	and	aPTT	Screen.
eTest	and	report.
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3.6 | Sensitivity of the aPTT, aPTT Lupus and 
aPTT Screen assays towards heparin and lupus 
anticoagulant
The	therapeutic	range	for	the	aPTT	assays	was	shorter	than	for	the	
comparator	 agents:	 lower	 (0.3	IU/mL)	 and	upper	 (0.7	IU/mL)	 limits	
for	 the	 coagulation	 time	 (seconds)	were	46.1-	57.4	 (aPTT)	 vs	 55.2-	
74.2	(Actin	FS);	53.9-	69.9	(aPTT	Lupus)	vs	55.7-	74.7	(Actin	FSL);	and	
56.4-	86.5	(aPTT	Screen)	vs	57.6-	79.8	(Pathromtin	SL).	aPTT	Screen	
showed	 the	 steepest	 response	 to	 UFH	 in	 UFH-	treated	 plasma	
samples,	demonstrating	the	greatest	sensitivity	towards	this	antico-
agulant,	while	aPTT	demonstrated	the	lowest	sensitivity	(Figure	1B).	
Using	either	aPTT	Lupus	or	aPTT	Screen,	more	than	80%	of	samples	
within	an	anti-	Xa	activity	range	of	0.3-	0.7	IU/mL	resulted	in	a	meas-
urable	 clotting	 time.	The	 relative	differences	 in	 clotting	 time	 ratio	
were	0.97	 (aPTT	vs	Actin	FS),	0.95	 (aPTT	Lupus	vs	Actin	FSL)	and	
0.94	(aPTT	Screen	vs	Pathromtin	SL).
Activated	partial	 thromboplastin	 time	Lupus	demonstrated	 the	
greatest	 sensitivity	 towards	 LA	 antibodies,	 with	 the	 steepest	 re-
sponse	 to	 LA	 in	 LA-	positive	 plasma	 samples	 (Figure	1C).	 As	 with	
Assay Evaluation Acceptance criteriac
Freiburg Sheffield
Lot 1 Lot 2
PT	Reca n 129 135
Slope	(Passing–Bablok) 1.00 ± 0.10 1.006 0.984
Intercept NA 0.006 0.033
Pearson’s	r ≥0.900 1.000 1.000
Bias	at	1.0	INR NA 0.0119 0.0175
PT	Owrena n 145
Slope	(Passing–Bablok) 1.00 ± 0.10 0.982
Intercept NA 0.00947
Pearson’s	r ≥0.900 1.000
Bias	at	1.0	INR 1	≤	0.10 −0.008
aPTTb n 139 129
Slope	(Passing–Bablok) 1.00 ± 0.10 1.000 1.000
Intercept NA 0 0.100
Pearson’s	r ≥0.900 0.998 0.995
Difference in median 
of	normal	range	
samples
NA 0.15 0.05
aPTT	Lupusb n 145 125
Slope	(Passing–Bablok) 1.00 ± 0.10 0.996 1.009
Intercept NA 0.139 −0.130
Pearson’s	r ≥0.900 0.999 0.999
Difference in median 
of	normal	range	
samples
NA 0.20 0.20
aPTT	Screenb n 131 128
Slope	(Passing–Bablok) 1.00 ± 0.10 0.996 0.980
Intercept NA 0.507 0.604
Pearson’s	r ≥0.900 0.999 0.998
Difference in median 
of	normal	range	
samples
NA 0.35 0.10
aPTT,	activated	partial	thromboplastin	time;	INR,	international	normalized	ratio;	NA,	not	applicable;	
PT,	prothrombin	time.
aAnalyses	based	on	INR.
bAnalyses	based	on	seconds.
c	Units	for	acceptance	criteria	are	INR	for	PT	Rec	and	PT	Owren,	and	seconds	for	aPTT,	aPTT	Lupus	
and	aPTT	Screen.
TABLE  3 Method	comparison	between	
cobas t 711 and cobas t 511 analysers
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UFH,	aPTT	showed	the	lowest	sensitivity	to	LA.	The	relative	differ-
ences	in	clotting	time	ratio	were	1.00	(aPTT	vs	Actin	FS),	1.04	(aPTT	
Lupus	vs	Actin	FSL)	and	0.96	(aPTT	Screen	vs	Pathromtin	SL).
4  | DISCUSSION
The	five	assays	demonstrated	excellent	analytical	performance	on	
both	 the	 cobas t 711 and cobas t	 511	 analysers.	Overall,	 CVs	 for	
within-	run	precision	were	≤1.3%	and	those	for	total	reproducibility	
were	≤6.3%;	lot-	to-	lot	comparisons	with	each	assay	showed	a	high	
level	of	consistency	across	all	sites.	Furthermore,	each	of	the	five	as-
says	performed	on	the	cobas t	711	analyser	showed	good	agreement	
with	the	commercially	available	assays/platforms	used	as	comparator	
methods,	 which	 have	 previously	 demonstrated	 favourable	 perfor-
mance	for	the	measurement	of	their	respective	analytes.34-36
The	reference	range	in	apparently	healthy	volunteers	measured	
with	the	aPTT	assay	was	consistent	with	those	previously	reported	
for	other	assays/platforms,20,34,35	and	the	reference	ranges	for	the	
aPTT	Lupus	and	aPTT	Screen	assays	were	in	line	with	those	of	the	
aPTT	assay.	The	reference	range	for	the	PT	Rec	assay	(8.4-	10.6	sec-
onds)	was	slightly	lower	than	that	previously	reported	for	similar	as-
says.34,37	Reference	ranges	for	each	assay	were	consistent	whether	
fresh	or	frozen	samples	were	used,	and	with	two	different	types	of	
sample	tube.
Together,	these	assays	provide	core	laboratories	with	a	method	
for	 monitoring	 anticoagulant	 therapy	 and	 for	 screening	 for	 spe-
cific	 coagulation	 abnormalities.	 For	 example,	 the	 PT	 Rec	 and	 PT	
TABLE  4 Lot-	to-	lot	comparison	on	the	cobas t 711 analyser
Assay Evaluation Acceptance criteriac
Freiburg Sheffield Debrecen
Lot 2 vs 1 Lot 3 vs 2 Lot 1 vs 3
PT	Reca n 129 135 129
Slope	(Passing–Bablok) 1.00 ± 0.10 1.000 1.000 1.008
Intercept NA 0.010 0.010 −0.013
Pearson’s	r ≥0.975 1.000 1.000 1.000
Bias	at	1.0	INR NA 0. 01 0. 01 −0.00476
PT	Owrena n 144 132d 135
Slope	(Passing–Bablok) 1.00 ± 0.10 1.002 0.989 1.000
Intercept NA −0.00243 0.0219 −0.0070
Pearson’s	r ≥0.950 1.000 1.000 1.000
Bias	at	1.0	INR NA 0.000 0.011 −0.007
aPTTb n 139 128 145
Slope	(Passing–Bablok) 1.00 ± 0.10 0.979 1.009 1.013
Intercept NA 0.704 0.156 −0.595
Pearson’s	r ≥0.975 0.999 0.999 0.999
Difference in median of normal 
range	samples
NA 0.30 0.40 0.30
aPTT	Lupusb n 147 125 151
Slope	(Passing–Bablok) 1.00 ± 0.10 0.943 1.014 1.031
Intercept NA 1.38 0.174 −1.04
Pearson’s	r ≥0.975 0.999 1.000 1.000
Difference in median of normal 
range	samples
NA 0.8 0.4 0.4
aPTT	Screenb n 131 129 144
Slope	(Passing–Bablok) 1.00 ± 0.10 1.023 0.987 0.992
Intercept NA −0.707 0.357 0.222
Pearson’s	r ≥0.975 0.998 0.999 0.999
Difference in median of normal 
range	samples
NA 0.45 0.30 0.15
aPTT,	activated	partial	thromboplastin	time;	INR,	international	normalized	ratio;	NA,	not	applicable;	PT,	prothrombin	time.
aAnalyses	based	on	INR.
bAnalyses	based	on	seconds.
cUnits	for	acceptance	criteria	are	INR	for	PT	Rec	and	PT	Owren,	and	seconds	for	aPTT,	aPTT	Lupus	and	aPTT	Screen.
dAnalysis	performed	at	Vienna	site.
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Owren	 assays	 are	 intended	 to	 aid	 in	 the	 management	 of	 vitamin	
K	 antagonist	 therapy	 and	 PT	Rec	may	 also	 be	 used	 as	 a	 diagnos-
tic	 tool	 for	 liver	 function	 testing.17,23,28,38	Compared	with	PT	Rec,	
the	PT	Owren	assay	is	designed	to	be	less	sensitive	to	interference	
by	 lupus	antibodies	and	 is	 insensitive	to	variations	 in	 factor	V	and	
fibrinogen;	 the	PT	 clotting	 time	measured	with	both	assays	 is	 not	
influenced	 by	 therapeutic	 plasma	 concentrations	 of	 UFH	 or	 low-	
molecular-	weight	heparin	(data	not	shown).28	The	aPTT	assays	pro-
vide	a	means	of	screening	for	abnormalities	in	intrinsic	coagulation	
pathway	factors	VIII,	 IX,	XI,	XII	and	common	pathway	factors	II,	V,	
F IGURE  1 Reference	Ranges	for	the	
Five	Assaysa	(A)	and	Evaluation	of	aPTT	
Assay	Sensitivity	to	Unfractionated	
Heparin	(UFH)	and	Lupus	Anticoagulant	
(LA),	Shown	as	Therapeutic	Ranges	of	
UFH	(B)	and	Comparative	LA	Sensitivity	of	
the	Roche	aPTT	Assays	on	the	cobas t 711 
Analyser	(C).	aFor	each	assay,	200	fresh	
samples	(0.109M/3.2%	citrate	in	Sarstedt	
tubes)	were	measured	using	three	
reagent	lots.	Boxes	depict	the	median	
value	and	reference	range	(2.5th	and	
97.5th	percentiles);	whiskers	represent	
minimum	and	maximum	values.	aPTT,	
activated	partial	thromboplastin	time;	PT,	
prothrombin	time
     |  9KITCHEN ET al.
X	and	fibrinogen.18,20,25,29	An	aPTT	test	may	be	required	as	part	of	
pre-	surgical	evaluation	for	bleeding	tendencies,	for	monitoring	UFH	
therapy,	or	following	treatment	with	thrombin	inhibitors	(eg,	bivali-
rudin,	argatroban,	or	dabigatran).10,12,14	Additionally,	compared	with	
the	aPTT	Screen	assay,	the	aPTT	assay	has	reduced	lupus	sensitiv-
ity,	while	the	aPTT	Lupus	assay	has	increased	lupus	sensitivity.	The	
aPTT	Screen	assay	has	 the	highest	 sensitivity	 towards	UFH,	 com-
pared	with	the	aPTT	and	aPTT	Lupus	assays.
Importantly,	 measurements	 with	 each	 assay	 showed	 good	
agreement	when	performed	on	 the	cobas t 711 and cobas t 511 
analysers,	thus	demonstrating	equivalence	between	the	two	plat-
forms.	 Both	 systems	 are	 built	 from	 functionally	 identical	 com-
ponents	 and	 implement	 identical	 assay	 processes	 using	 identical	
reagents	and	disposables.	The	systems	provide	automatic	reagent	
reconstitution,	continuous	loading	of	all	samples,	reagents	and	cu-
vettes,	 and	a	high	 reagent	 storage	 capacity	 and	are	 thus	 aligned	
with	 the	 need	 for	 efficient	 workflow	 in	 core	 laboratories;	 the	
main	 difference	 between	 platforms	 is	 the	 level	 of	 throughput,	
with	 the	 cobas t	 711	 platform	 being	 classed	 as	 high-	throughput	
(390	tests/h)	and	the	cobas t	511	platform	as	medium	throughput	
(195	tests/h).	Laboratory	coagulation	testing	accounts	for	around	
one-	fifth	 of	 the	 total	 sample	 workload	 of	 typical	 core	 laborato-
ries.	For	example,	in	the	core	laboratory	at	Debrecen,	~10%	of	the	
4.5	million	tests	per	year	are	coagulation	tests;	however,	the	actual	
workload	is	much	higher	due	to	the	requirement	for	further	tests	
such	as	those	for	LA,	factor	deficiencies	and	von	Willebrand	dis-
ease.	 Therefore,	 improvements	 in	 throughput	 and	 efficiency	 are	
highly	 desirable	 and	 can	 result	 in	 significant	 capacity	 gains	 and	
cost	savings.
Strengths	of	the	study	include	the	multicentre	design	(includ-
ing	 four	 core	 laboratories	 in	 different	 European	 countries)	 and	
adherence	to	CLSI	guidelines.	Furthermore,	method	comparisons	
were	 performed	 against	 relevant	 commercially	 available	 assays/
platforms	 and	 reference	 ranges	were	 established	 for	 each	 assay	
using	samples	from	200	apparently	healthy	volunteers.	Although	
not	 a	 limitation	 of	 the	 study	 design,	 which	 aimed	 to	 assess	 the	
analytical	performance	of	the	assays	and	their	interchangeability	
with	 existing	 commercially	 available	 methods,	 the	 authors	 note	
that	this	study	did	not	aim	to	assess	the	clinical	performance	of	the	
assays	on	the	cobas t	analysers	in	terms	of	their	ability	to	detect	
abnormalities	 in	 coagulation	 factors,	 or	 assess	 therapeutic	 drug	
levels;	 nevertheless,	 checks	of	 factor-	deficient	 samples	 included	
in	the	study	showed	that	the	assays	were	able	to	detect	the	defi-
ciencies	adequately	(data	not	shown).
In	summary,	based	on	the	excellent	analytical	performance	and	
good	agreement	with	relevant	comparator	methods,	the	five	coagu-
lation	assays	on	the	novel	cobas t 711 and cobas t 511 analysers are 
suitable	for	routine	use	in	core	laboratories.
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